Please ensure Javascript is enabled for purposes of website accessibility

Why Epizyme, Tribune Media, and Revlon Jumped Today

By Dan Caplinger - Jun 15, 2017 at 4:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

On a rocky day for the market, these stocks climbed. Find out why.

Thursday was a rocky day on Wall Street, although by the end of the session, things looked a lot better than they had early in the morning. Major benchmarks were down as much as 1% when technology stocks both in the U.S. and abroad took a substantial hit, and market participants theorized that the bull market that had taken key players in the industry to new heights was overdue for a downward correction. Yet that negative mood moderated by the end of the trading session, and the Dow and S&P 500 finished with only modest losses.

Positive news from some key individual stocks also helped stoke optimism across the market, and Epizyme (EPZM -5.09%), Tribune Media (NYSE: TRCO), and Revlon (REV -3.17%) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you why they did so well.

Epizyme makes it two days in a row

Shares of Epizyme climbed more than 17%, following up on their 10% rise on Wednesday. Yesterday's gains were spurred by positive clinical trial data from its tazemetostat treatment for lymphoma, and today, investors looked at potential second-order impacts from favorable trial results. In particular, several reports suggested that major players in the pharmaceutical and biotechnology space have a lot of spare cash that they could use for mergers and acquisitions, and if they decide that tazemetostat has enough potential, it might spur them to make a buyout bid for Epizyme. Moreover, stock analysts at Oppenheimer repeated their outperform rating on the stock, keeping their share price target of $26, or close to double what Epizyme stock fetches currently.

Epizyme logo.

Image source: Epizyme.

Tribune gets some help

Tribune Media stock gained 5% after an appeals court ruling improved the chances of a major deal going through. The media company is in the process of consummating a deal to sell itself to Sinclair Broadcast Group (SBGI -0.71%) for $3.9 billion, but the buyout was contingent on the move from the Federal Communications Commission to change rules governing television station ownership to allow greater concentrations of stations owned by a single entity. With Tribune having 42 stations and Sinclair having 173, the purchase would have violated old rules limiting ownership to markets totaling 39% of U.S. households. The appeals court chose not to grant an emergency order to block the FCC decision, which would have stopped the Sinclair-Tribune purchase. Tribune shareholders will receive $43.50 per share in cash if the deal goes through, and today's jump eliminated about half of the discount in Tribune stock from that buyout price.

Revlon looks prettier

Finally, shares of Revlon rose almost 5%. The cosmetics giant has been getting positive attention from major shareholder Ron Perelman, who reported massive acquisitions of the stock over the past week. Perelman-related entities spent $1.9 million last Thursday, $3.9 million last Friday, and just over $1 million on Monday to purchase a total of almost 350,000 shares of Revlon, boosting the total owned by those entities to more than 42.4 million shares. The stock has been performing poorly because of sluggish results in its fiscal first quarter, which included a drop of 6% in organic sales figures and declining gross margin. Yet the billionaire sees the decline as a buying opportunity, with the latest purchases adding to money that Perelman already spent in May to acquire shares. With Revlon in the midst of a turnaround, a lot is riding on the cosmetic company's ability to gain traction in a tough environment for retail.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Revlon, Inc. Stock Quote
Revlon, Inc.
$3.97 (-3.17%) $0.13
Sinclair Broadcast Group, Inc. Stock Quote
Sinclair Broadcast Group, Inc.
$25.02 (-0.71%) $0.18
Epizyme Stock Quote
$0.48 (-5.09%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.